Skip to content Skip to footer

genome editing

developing first-in-class

advanced therapy

medicinal products (ATMPs)

New HIV therapy with the chance of a cure

Our vision to improve the lives of people with HIV.

Introduction video for the Innovation Award 2023 on behalf of WRG Wirtschaftsförderung Region Göttingen GmbH.



Oliver Ahnfeld

Co-Founder CEO/CFO

PD Dr. Jan Chemnitz MBA

Co-Founder CEO/CSO

Dr. Niklas Beschorner

Co-Founder Head of RnD

Dr. Maike Voges

Co-Founder Head of QM

Stay up-to-date

Latest News

Next scientific publication is online!
Our new scientific publication is now published in Plos One. In this publication we present an extensive preclinical evaluation of our Brec1 technology and lentiviral vectors expressing the Brec1 transgene. This included detailed functional analysis of potential genomic off-target sites, assessing vector safety by investigating…
PROVIREX took third place at the 21st Göttingen Innovation Award!
We took third place in the Göttingen Innovation Award 2023 in the category "Companies with up to 20 employees"! Many thanks to WRG Wirtschaftsförderung Region Göttingen GmbH and all sponsors. Newspaper article about it. (only in german) Application video: (only in german)
Official laying of the foundation stone for the new tecHHub building!
In rainy and stormy weather, the official ceremony for the start of the construction of the new tecHHub building for our production rooms in Hamburg was held today with Senator Dr. Melanie Leonhard. The planned completion date is the end of 2023. We are happy…

Working together

Shareholders & Partners

Genome Editing Therapies GmbH

Luruper Hauptstraße 1
22547 Hamburg


Copyright © PROVIREX Genome Editing Therapies GmbH 2023